Zoetis Inc. Annual Report, Year Ended Dec 31, 2015

Zoetis Inc.'s 2015 10-K filing reveals a company that has successfully transitioned into an independent, global leader in animal health. For the year ended December 31, 2015, Zoetis reported total revenue of $4.765 billion, with a balanced contribution from its United States (49%) and International (50%) segments. The company demonstrates a strong product portfolio serving both livestock (62% of revenue) and companion animals (37% of revenue), with key product lines like ceftiofur, Revolution, and Draxxin contributing significantly to overall sales. Zoetis continues to invest in research and development, with $364 million allocated in 2015, focusing on both new product development and lifecycle innovation to maintain its competitive edge. The company also highlights its commitment to operational efficiency, with a program aimed at simplifying its product portfolio and optimizing its supply chain. Investors should note the company's strategic acquisitions, including Pharmaq for aquaculture and assets from Abbott Animal Health to bolster its companion animal offerings. While facing challenges such as foreign currency fluctuations (which negatively impacted revenue by 8% in 2015) and the ongoing global economic environment, Zoetis maintains a robust liquidity position and is focused on disciplined capital allocation and long-term value creation. The company also continues to manage its relationship with Pfizer through transitional services agreements, ensuring operational continuity.